Amgen’s Aimovig and Eli Lilly’s Emgality Feel the Heat From Strong Uptake of Biohaven’s Nurtec ODT Among Primary Care Physicians for Migraine Prevention, According to Spherix Global Insights

EXTON, Pa.: EXTON, Pa., Oct. 12, 2021 /PRNewswire/ -- Following the May 2021 FDA approval of Biohaven's Nurtec ODT for the preventive treatment of episodic migraine, primary care physicians (PCPs) have readily adopted the gepant into their treatment armamentarium. However, PCP prescribing patterns appear ready to disrupt, rather than merely...

Click to view original post